Literature DB >> 11709757

Challenges in the development, licensure, and use of combination vaccines.

A S Postema1, M G Myers, R F Breiman.   

Abstract

Before substantial public health benefits associated with use of combination vaccines can be realized, a variety of challenges must be addressed. In February 2000, the National Vaccine Program Office convened the International Symposium on Combination Vaccines to explore solutions for barriers to development, licensure, and use of safe and effective combination vaccines. The symposium focused on the following questions: (1) What immunologic standards should be used to evaluate new combination vaccines? (2) How should correlates of protection be developed, and how should the data they provide be interpreted? (3) What sample size is adequate for prelicensure safety trials of combination vaccines? (4) Should standards for evaluation of combination vaccines containing licensed components be different from standards for evaluation of combinations containing unlicensed components? (5) How can the "great expectations" of postlicensure surveillance be realized? Available data relevant to these issues were presented, providing a foundation for furthering the science of combination vaccines.

Mesh:

Substances:

Year:  2001        PMID: 11709757     DOI: 10.1086/322560

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  A call to restructure the drug development process: government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care.

Authors:  Thomas C Jones
Journal:  Sci Eng Ethics       Date:  2005-10       Impact factor: 3.525

2.  Adsorption of Toll-Like Receptor 4 Agonist to Alum-Based Tetanus Toxoid Vaccine Dampens Pro-T Helper 2 Activities and Enhances Antibody Responses.

Authors:  Juliana Bortolatto; Luciana Mirotti; Dunia Rodriguez; Eliane Gomes; Momtchilo Russo
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

3.  Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.

Authors:  Freya J I Fowkes; Julie A Simpson; James G Beeson
Journal:  BMC Med       Date:  2013-10-30       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.